AI Summary
✦ ClarthaValuation Metrics
Trading 19.4% below historical median. Valuation is declining — currently in the strongly undervalued zone (z-score: -0.78). Confidence: 50%.
Live forward EPS implies next-12-month EPS of ₹35.80. Applying the stock's normalized valuation corridor produces a fair range of ₹1,259.44 to ₹2,783.09, with base value near ₹1,490.71 (+176.1% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹35.80
Forward P/E
15.1x
Base Fair Value
₹1,490.71
Fair Range
₹1,259.44 - ₹2,783.09
Upside To Base
+176.1%
Estimate Source
Live forward EPS
Growth Estimate
+28.4%
5Y Average
44.15
Current
33.56
Overvalued
77.74
Undervalued
35.18
5Y Average
26.36
Current
18.09
Overvalued
35.01
Undervalued
11.27
5Y Average
11.49
Current
7.88
Overvalued
15.25
Undervalued
4.91
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
AKUMS DRUGS AND PHARMA L AKUMSPharmaceuticals | +9.6% | 5.9% | 43.8x Undervalued | -34% vs avg | +45.4% |
BLUE JET HEALTHCARE LTD BLUEJETPharmaceuticals | -17.4% | 26.5% | 43.7x Undervalued | -34% vs avg | -25.8% |
CAPLIN POINT LAB LTD. CAPLIPOINTPharmaceuticals | +19.0% | 29.3% | 31.2x Undervalued | -53% vs avg | +22.1% |
ALIVUS LIFE SCIENCES LTD ALIVUSPharmaceuticals | +6.4% | 23.3% | 28.0x Undervalued | -58% vs avg | +43.4% |
CONCORD BIOTECH LIMITED CONCORDBIOPharmaceuticals | +26.2% | 24.8% | 48.8x Undervalued | -27% vs avg | -14.9% |
ASTRAZENECA PHARMA IND LT ASTRAZENPharmaceuticals | +20.4% | 8.2% | 107.4x Premium | +62% vs avg | -6.9% |
COHANCE LIFESCIENCES LTD COHANCEPharmaceuticals | -23.1% | 5.0% | 162.0x Premium | +144% vs avg | -52.7% |
JEENA SIKHO LIFECARE LTD trades at a discount (30.3x vs peer avg 66.4x), suggesting potential undervaluation relative to the Pharmaceuticals cohort. Peers include AKUMS DRUGS AND PHARMA L, BLUE JET HEALTHCARE LTD, CAPLIN POINT LAB LTD. — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Financial chart data is not available for this company right now.
Results
Income statement data not available.
All values in ₹ Crores unless otherwise stated. Source: Company filings.